Proteomics’ finger-prick test for detecting oxidative stress in muscles has the potential to cash in on the sports injury and recovery sector.
Perth-based med tech Proteomics International has been granted a European patent for its finger-prick technology OxiDx.
OxiDx offers a comprehensive solution for monitoring levels of oxidative stress by measuring levels of muscle damage using a simple finger-prick blood sample to detect protein biomarkers in the blood.
In professional sports, muscle injuries are the most frequent cause of incapacity, accounting for up to 55% of all injuries. In 2019, $1.4 billion was spent on treating potentially avoidable sports injuries in Australia alone.
Proteomics’ PIQ Lab says the European patent is a significant milestone for commercialisation of this innovative technology in the key markets of Europe.
“It is exciting to see the uniqueness of the OxiDx technology being recognised in leading markets, and we look forward to the technology rolling out,” said PIQ’s managing director, Dr Richard Lipscombe.
